Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6453198 | 0.82 | SMN1; SMN2 (0.57) | GABRA1GABRB1GABRA2GABRB2ADORA2A | |
| SCHEMBL6453065 | 0.82 | GRK6 (0.46) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6448741 | 0.77 | GRK6 (0.43) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL11320053 | 0.74 | SMN1; SMN2 (0.53) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6452609 | 0.74 | ADORA2A (0.58) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6449080 | 0.72 | GRK6 (0.46) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6448721 | 0.72 | IDO1 (0.47) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6448693 | 0.72 | IDO1 (0.45) | ADORA2ATDP1SMN1; SMN2NPC1ALPL | |
| SCHEMBL6450018 | 0.72 | GABRA1 (0.36) | GABRA1GABRB1GABRA2GABRB2ADORA2A | |
| SCHEMBL6460656 | 0.72 | SMN1; SMN2 (0.43) | ADORA2ATDP1SMN1; SMN2NPC1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GABRA1 4078/4885GABRB1 3304/4885GABRA2 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.